Alessandro Poma

Dr. Alessandro Poma

University College London, UK
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2013 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
APAlessandro Poma
Alessandro Poma
AGAntonio Guerreiro
Antonio Guerreiro
MWMichael J. Whitcombe
Michael J. Whitcombe
Elena PiletskaElena Piletska
Elena Piletska
TTTony Turner
Tony Turner
SPSergey Piletsky
Sergey Piletsky

11 February 2016 in Nature Protocols
Verified
Journal Article
Closed access
FCFrancesco Canfarotta
Francesco Canfarotta
APAlessandro Poma
Alessandro Poma
AGAntonio Guerreiro
Antonio Guerreiro
SPSergey Piletsky
Sergey Piletsky

23 September 2011 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
CMCosimino Malitesta
Cosimino Malitesta
EMElisabetta Mazzotta
Elisabetta Mazzotta
Rosaria Anna PiccaRosaria Anna Picca
Rosaria Anna Picca
APAlessandro Poma
Alessandro Poma
Iva ChianellaIva Chianella
Iva Chianella
SPSergey Piletsky
Sergey Piletsky

15 November 2024 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
XMXiaohan Ma
Xiaohan Ma
YTYaxin Tian
Yaxin Tian
RYRen Yang
Ren Yang
HWHaowei Wang
Haowei Wang
LALatifa W. Allahou
Latifa W. Allahou
APAlessandro Poma
Alessandro Poma
Nanotechnology holds immense promise in revolutionising healthcare, offering unprecedented opportunities in diagnostics, drug delivery, cancer therapy, and combating infectious diseases. This review explores the multifaceted landscape of nanotechnology in healthcare while addressing the critical aspects of safety and environmental risks associated with its widespread application. Beginning with an introduction to the integration of nanotechnology in healthcare, we first delved into its categorisation and various materials employed, setting the stage for a comprehensive understanding of its potential. We then proceeded to elucidate the diverse healthcare applications of nanotechnology, spanning medical diagnostics, tissue engineering, targeted drug delivery, gene delivery, cancer therapy, and the development of antimicrobial agents. The discussion extended to the current situation surrounding the clinical translation and commercialisation of these cutting-edge technologies, focusing on the nanotechnology-based healthcare products that have been approved globally to date. We also discussed the safety considerations of nanomaterials, both in terms of human health and environmental impact. We presented the in vivo health risks associated with nanomaterial exposure, in relation with transport mechanisms, oxidative stress, and physical interactions. Moreover, we highlighted the environmental risks, acknowledging the potential implications on ecosystems and biodiversity. Lastly, we strived to offer insights into the current regulatory landscape governing nanotechnology in healthcare across different regions globally. By synthesising these diverse perspectives, we underscore the imperative of balancing innovation with safety and environmental stewardship, while charting a path forward for the responsible integration of nanotechnology in healthcare. Graphical abstract

1 December 2010 in Trends in Biotechnology
Verified
Journal Article
Closed access
APAlessandro Poma
Alessandro Poma
TTTony Turner
Tony Turner
SPSergey Piletsky
Sergey Piletsky

1 April 2020 in Trends in Biotechnology
Verified
Journal Article
Closed access
SPStanislav Piletsky
Stanislav Piletsky
FCFrancesco Canfarotta
Francesco Canfarotta
APAlessandro Poma
Alessandro Poma
Alessandra Maria BossiAlessandra Maria Bossi
Alessandra Maria Bossi
SPSergey Piletsky
Sergey Piletsky